Sarepta Therapeutics, Inc.
SRPT
$19.04
-$0.09-0.47%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.89% | -32.73% | -14.52% | 68.38% | 80.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.89% | -32.73% | -14.52% | 68.38% | 80.15% |
| Cost of Revenue | -23.14% | 117.92% | 16.92% | 59.19% | -38.28% |
| Gross Profit | 3.69% | -186.19% | -80.34% | 83.24% | 263.04% |
| SG&A Expenses | -18.47% | -21.71% | -28.32% | -0.65% | 5.22% |
| Depreciation & Amortization | 14.98% | 12.65% | 12.46% | 10.98% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -64.37% | 71.73% | 3.88% | 36.27% | 176.11% |
| Operating Income | 219.32% | -353.64% | -383.29% | 16,587.45% | -960.58% |
| Income Before Tax | 189.48% | -262.04% | -670.63% | 1,031.60% | -1,025.30% |
| Income Tax Expenses | -80.91% | -64.15% | -3,670.13% | -707.76% | 1,100.79% |
| Earnings from Continuing Operations | 173.96% | -277.84% | -635.38% | 2,947.86% | -1,338.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 173.96% | -277.84% | -635.38% | 2,947.86% | -1,338.98% |
| EBIT | 219.32% | -353.64% | -383.29% | 16,587.45% | -960.58% |
| EBITDA | 227.07% | -335.18% | -238.83% | 1,476.67% | -765.33% |
| EPS Basic | 168.59% | -263.39% | -609.42% | 2,841.43% | -1,296.02% |
| Normalized Basic EPS | 208.21% | -335.38% | -347.15% | 4,068.18% | -853.34% |
| EPS Diluted | 162.61% | -267.36% | -631.44% | 2,662.81% | -1,346.62% |
| Normalized Diluted EPS | 193.18% | -365.21% | -360.22% | 3,913.69% | -894.42% |
| Average Basic Shares Outstanding | 7.83% | 8.84% | 5.08% | 3.58% | 3.59% |
| Average Diluted Shares Outstanding | 25.22% | -3.39% | -0.21% | 7.54% | -1.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |